STERIS plc
STEAPI behind this page
STE Q3 2026 request
Playground key active
/api/financials?ticker=STE&year=2026&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2026 | Q3 2025 | YoY |
|---|---|---|---|
| Revenue | 1,496.2 | 1,370.6 | +9.2% |
Show Product Lines breakouts |
|||
| Capital equipment · Applied Sterilization Technologies | 10.2 | 5 | +104.0% |
| Capital equipment · Healthcare | 272.1 | 254.8 | +6.8% |
| Capital equipment · Life Sciences: | 33.3 | 31.1 | +7.1% |
| Consumables · Healthcare | 387.1 | 358.2 | +8.1% |
| Consumables · Life Sciences: | 75.9 | 68.7 | +10.5% |
| Product | 778.9 | 718.3 | +8.4% |
| Service | 717.3 | 652.2 | +10.0% |
| Service · Applied Sterilization Technologies | 276.4 | 253.1 | +9.2% |
| Service · Healthcare | 404.7 | 363 | +11.5% |
| Service · Life Sciences: | 36.5 | 36.6 | -0.3% |
Show Business Segments breakouts |
|||
| Applied Sterilization Technologies | 286.6 | 258.1 | +11.0% |
| Healthcare | 1,063.8 | 976 | +9.0% |
| Life Sciences: | 145.8 | 136.4 | +6.9% |
Show Geography breakouts |
|||
| IE | 26.7 | 24.1 | +10.8% |
| Non Us | 382.3 | 343.9 | +11.2% |
| US | 1,087.1 | 1,002.6 | +8.4% |
| Cost of Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 418.2 | 371.7 | +12.5% |
| Service | 422.5 | 388.5 | +8.8% |
| Cost of Revenue | 840.7 | 760.2 | +10.6% |
Show Business Segments breakouts |
|||
| Applied Sterilization Technologies · Operating Segments | 141.1 | 127.9 | +10.3% |
| Healthcare · Operating Segments | 615.6 | 552.4 | +11.4% |
| Life Sciences: · Operating Segments | 65.6 | 60.9 | +7.7% |
| Gross Profit | 655.5 | 610.3 | +7.4% |
| Selling, General & Administrative | 352.3 | 335.5 | +5.0% |
Show Business Segments breakouts |
|||
| Applied Sterilization Technologies · Operating Segments | 15.4 | 13.3 | +15.8% |
| Healthcare · Operating Segments | 164.8 | 153.5 | +7.4% |
| Life Sciences: · Operating Segments | 15.6 | 15 | +4.0% |
| Research & Development | 29.5 | 27.4 | +7.7% |
Show Business Segments breakouts |
|||
| Applied Sterilization Technologies · Operating Segments | 0.8 | 1.2 | -33.3% |
| Healthcare · Operating Segments | 25.2 | 23.2 | +8.6% |
| Life Sciences: · Operating Segments | 2.8 | 2.4 | +16.7% |
| Restructuring Costs | 0.4 | 2.2 | -81.8% |
| Operating Expenses | 382.3 | 365 | +4.7% |
| Operating Income | 273.2 | 245.3 | +11.4% |
Show Business Segments breakouts |
|||
| Applied Sterilization Technologies | 129.2 | 115.8 | +11.6% |
| Corporate | -106 | -100.8 | -5.2% |
| Healthcare | 258.1 | 246.9 | +4.5% |
| Life Sciences: | 61.8 | 58.1 | +6.4% |
| Segment operating income | 343.1 | 320 | +7.2% |
| Interest Expense | 14.9 | 19.1 | -22.0% |
| Other Non-Operating Income (Expense) | -2.9 | -2.4 | -20.8% |
| Other Operating Income Expense Net | 3.3 | -0.1 | +3400.0% |
| Non-Operating Income (Expense) | 15.3 | 16.5 | -7.3% |
| Income Before Taxes | 257.8 | 228.7 | +12.7% |
| Income Tax Expense (Benefit) | 63.5 | 55.4 | +14.6% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | 194.3 | 173.4 | +12.1% |
| Net Income | 194.3 | 173.3 | +12.1% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 1.5 | -0.2 | +850.0% |
| Retained Earnings | 192.9 | 173.5 | +11.2% |
| Net Income Loss Attributable To Noncontrolling Interest | 1.5 | -0.2 | +850.0% |
| Net Income | 192.9 | 173.5 | +11.2% |
| Income Loss From Continuing Operations Per Basic Share | 1.96 | 1.76 | +11.4% |
| EPS (Basic) | 1.96 | 1.76 | +11.4% |
| Income Loss From Continuing Operations Per Diluted Share | 1.96 | 1.75 | +12.0% |
| EPS (Diluted) | 1.96 | 1.75 | +12.0% |
| Common Stock Dividends Per Share Declared | 0.63 | 0.57 | +10.5% |
| Comprehensive Income | 226.2 | -34.9 | +748.1% |
| Other Comprehensive Income | 33.4 | -208.4 | +116.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 33.4 | -208.4 | +116.0% |
| Wtd Avg Shares (Basic) | 98.2 | 98.5 | -0.3% |
| Wtd Avg Shares (Diluted) | 98.6 | 98.9 | -0.3% |
Balance Sheet
| Metric | Q3 2026 | Q3 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 423.7 | 155,178 | -99.7% |
| Accounts Receivable | 990.6 | 915,199 | -99.9% |
| Inventory | 673.5 | 649,558 | -99.9% |
| Other Prepaid Expense Current | 198.4 | 177,918 | -99.9% |
| Total Current Assets | 2,286.2 | 1,897,853 | -99.9% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,133.2 | — | — |
Show Geography breakouts |
|||
| IE | 90.5 | — | — |
| Non Us | 967.8 | — | — |
| US | 1,074.9 | — | — |
| Operating Lease Right-of-Use Assets | 154.9 | — | — |
| Goodwill | 4,232 | — | — |
| Other Non-Current Assets | 93.6 | 67,679 | -99.9% |
| Total Assets | 10,591.4 | — | — |
Show Business Segments breakouts |
|||
| Applied Sterilization Technologies · Segment Continuing Operations | 3,586.9 | — | — |
| Healthcare Products and Life Sciences · Segment Continuing Operations | 7,004.5 | — | — |
Show Statement Operating Activities Segment breakouts |
|||
| Segment Continuing Operations | 10,591.4 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 1,691.5 | 1,923,020 | -99.9% |
| Current Liabilities | |||
| Accounts Payable | 285.1 | 238,298 | -99.9% |
| Accrued Income Taxes Current | 9.9 | — | — |
| Employee Related Liabilities Current | 188 | 160,785 | -99.9% |
| Operating Lease Liability Current | 34.4 | 32,451 | -99.9% |
| Accrued Liabilities | 405 | 334,586 | -99.9% |
| Total Current Liabilities | 922.3 | 891,120 | -99.9% |
| Non-Current Liabilities | |||
| Long-Term Debt | 1,898.4 | 2,038,725 | -99.9% |
| Deferred Income Taxes And Other Tax Liabilities Noncurrent | 414.5 | 453,125 | -99.9% |
| Operating And Finance Lease Obligation Noncurrent | 120.9 | 123,717 | -99.9% |
| Other Non-Current Liabilities | 67.4 | 73,129 | -99.9% |
| Total Liabilities | 3,423.5 | 3,579,816 | -99.9% |
| Long-Term Debt | 1,898.4 | — | — |
| Accrued Income Taxes Noncurrent | 1.9 | 6,527 | -100.0% |
| Other Liabilities | |||
| Minority Interest | 13.4 | 12,445 | -99.9% |
| Stockholders' Equity | |||
| Common Stock | 4,339.8 | 4,404,687 | -99.9% |
| Retained Earnings | 2,857.4 | 2,385,664 | -99.9% |
| Accumulated Other Comprehensive Income | -42.7 | — | — |
| Total Stockholders' Equity | 7,154.5 | 6,416,101 | -99.9% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 7,167.9 | 6,428.5 | +11.5% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -0.5 | -0.8 | +37.5% |
| Accumulated Other Comprehensive Income | -42.7 | -374.3 | +88.6% |
| Accumulated Translation Adjustment | -42.2 | -373.4 | +88.7% |
| Common Stock | 4,339.8 | 4,404.7 | -1.5% |
| Noncontrolling Interest | 13.4 | 12.4 | +8.1% |
| Retained Earnings | 2,857.4 | 2,385.7 | +19.8% |
| Total Liabilities & Equity | 10,591.4 | 10,008,362 | -99.9% |
Cash Flow Statement
| Metric | YTD Q3 2026 | YTD Q3 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 363.1 | 353.9 | +2.6% |
Show Business Segments breakouts |
|||
| Applied Sterilization Technologies · Segment Continuing Operations | 115.2 | 105.5 | +9.2% |
| Healthcare Products and Life Sciences · Segment Continuing Operations | 247.9 | 248.4 | -0.2% |
Show Statement Operating Activities Segment breakouts |
|||
| Segment Continuing Operations | 363.1 | 353.9 | +2.6% |
| Deferred Income Taxes | -0.2 | -23.8 | +99.2% |
| Stock-Based Compensation | 48.8 | 47.6 | +2.5% |
| Gain Loss On Sale Of Property Plant Equipment | 3.3 | 3 | +10.0% |
| Gain Loss On Disposition Of Business And Equity Investments Net | 0.3 | -4.5 | +106.7% |
| Other Non-Cash Items | 12.2 | -7.2 | +269.4% |
| Change in Accounts Receivable | 98.4 | 79.3 | +24.1% |
| Change in Inventory | -62.5 | -0.7 | -8828.6% |
| Change in Prepaid & Other Assets | 10 | -18.4 | +154.3% |
| Change in Accounts Payable | -5.8 | -7.5 | +22.7% |
| Increase Decrease In Accrued Liabilities | -26.5 | -4.5 | -488.9% |
| Net Cash from Operations | 1,006 | 887.3 | +13.4% |
| Investing Activities | |||
| Capital Expenditures | -278.8 | -299.2 | +6.8% |
| Proceeds From Sale Of Property Plant And Equipment | 10.4 | 4 | +160.0% |
| Payments To Acquire Investments | -6.8 | — | — |
| Payments To Acquire Businesses Net Of Cash Acquired | -20.1 | -53.7 | +62.6% |
Show Business Acquisition breakouts |
|||
| Other FY26 Acquisitions | -23.4 | — | — |
| Net Cash from Investing | -295.3 | 458.6 | -164.4% |
| Financing Activities | |||
| Repayments Of Senior Debt | -125 | -80 | -56.2% |
| Proceeds From Repayments Of Lines Of Credit | -34.8 | -319 | +89.1% |
| Payments Of Merger Related Costs Financing Activities | -0.3 | -0.3 | 0.0% |
| Share Repurchases | -161.2 | -211.1 | +23.6% |
| Payments Of Dividends Common Stock | -180 | -163.9 | -9.8% |
| Payments To Minority Shareholders | -1.4 | -1.6 | +12.5% |
| Proceeds From Payments For Other Financing Activities | 32.3 | 19.4 | +66.5% |
| Net Cash from Financing | -470.3 | -1,394.3 | +66.3% |
| Tax Withholding for Share Compensation | 11.2 | 11 | +1.8% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 11.6 | -3.4 | +441.2% |
| Net Change in Cash | 252 | -51.8 | +586.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 423.7 | 155.2 | +173.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.